Sponsors (7)
The bill creates clearer federal rules and stronger public-health enforcement for hemp‑derived cannabinoid products—benefiting consumers and compliant businesses—while imposing substantial compliance costs, narrower consumer access, and enforcement risks that will most heavily affect small producers and retailers.
Small businesses, manufacturers, and consumers gain a clearer federal regulatory framework that defines hemp-derived cannabinoid products, sets labeling/testing/manufacturing rules, and gives agencies an explicit process to identify cannabinoids.
Consumers, patients, and food-producers benefit from explicit prohibitions on higher‑risk products (e.g., high‑dose oral or inhalable cannabinoids, synthetic cannabinoids, food-animal products) combined with FDA inspection, detention, seizure, and preserved HHS/FDA oversight, which together strengthen public health protections.
Producers, importers, and distributors get non‑retroactive effective-date rules and updated cross‑references, reducing the risk of retroactive enforcement and legal ambiguity for products introduced after enactment.
Small manufacturers, retailers, and other sellers face substantial compliance costs, potential product removals, lost sales, and inventory disruptions from new prohibitions, reclassifications, labeling/renumbering requirements, inspections, and hold orders.
Consumers may lose access to some cannabinoid products previously sold as supplements or edibles if those products exceed new thresholds or are reclassified as prohibited.
Granting the Secretary broad delegated authority to designate chemicals as cannabinoids could create regulatory uncertainty for companies until HHS/FDA updates and publishes lists and guidance.
Based on analysis of 5 sections of legislative text.
Creates a new FD&C Act regulatory category for hemp-derived cannabinoid products, requires HHS to list covered cannabinoids, adds manufacturing/retail rules, enforcement powers, and criminal penalties.
Introduced January 22, 2026 by H. Morgan Griffith · Last progress January 22, 2026
Creates a new regulatory framework for hemp-derived cannabinoid products by defining “cannabinoid” and “cannabinoid hemp product,” requiring HHS/FDA to publish and maintain a list of covered cannabinoid compounds, and treating these products as subject to the Federal Food, Drug, and Cosmetic Act. The law adds labeling/manufacturing/testing requirements and retail-sale limits (including a sale-to-under-21 prohibition), expands FDA civil seizure and detention authority for covered products, and creates a new criminal penalty (up to 10 years) for knowing violations of the statute’s cannabinoid-related prohibitions.